Business
POLB 001 patent granted in South Africa
Poolbeg Pharma PLC has received notification of the official grant of its Immunomodulator II patent in South Africa for POLB 001, providing protection until December 2038 for the prevention of hypercytokinemia and severe influenza. This patent strengthens the company's intellectual property portfolio for POLB 001, a p38 MAP kinase inhibitor with potential applications in preventing cancer immunotherapy-induced Cytokine Release Syndrome and severe influenza, thereby enhancing its value and appeal to potential partners. Disclaimer*
About this update from Poolbeg Pharma Plc
Poolbeg Pharma plc POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza Patent decision strengthens Poolbeg's intellectual property portfolio 30 June 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg's Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and severe influenza until December 2038. POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong potential across multiple disease areas, including the prevention of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and severe influenza. POLB 001 holds the potential to address significant unmet needs affecting patients and healthcare systems globally. Poolbeg has a robust portfolio of patents in place covering p38 MAP kinase inhibitors for the treatment of severe influenza; and for POLB 001 for the prevention of hypercytokinemia. Additional patent applications have been filed to strengthen and complement Poolbeg's POLB 001 patent portfolio, particularly for cancer immunotherapy-induced CRS. Developing a strong intellectual property portfolio remains a key priority for Poolbeg, enhancing POLB 001's value and appeal to potential partners. Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "This latest patent grant reflects our commitment to further strengthen POLB 001's global IP portfolio, enhancing its value and attractiveness to prospective partners. POLB 001 holds the potential to significantly benefit patients and healthcare systems globally across multiple disease areas, and this patent represents another step forward in our mission to positively impact the lives of patients." Enquiries Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO +44 (0) 207 183 1499 [email protected] Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM) +44 (0) 207 220 0500 Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry D...
View stock analysis, news, and events for Poolbeg Pharma Plc